Article Text

AB0441 Effectiveness of Tocilizumab in Monotherapy in Patients with Rheumatoid Arthritis in Clinical Practice
  1. B. Magallares1,
  2. E. Quesada-Masachs2,
  3. M. Hernández3,
  4. M. Lisbona4,
  5. P. Moya1,
  6. M. Moreno5,
  7. V. Torrente-Segarra6,
  8. D. Reina7,
  9. J. Narváez8,
  10. S. Marsal2,
  11. R. Sanmartí3,
  12. J. Calvet5,
  13. J. Maymό4,
  14. C. Díaz-Torné1,
  15. A. Gόmez5,
  16. H. Corominas7,
  17. J. Nolla8,
  18. A. Rodríguez de la Serna1
  1. 1Hospital Sant Pau
  2. 2Hospital Vall d'Hebron
  3. 3Hospital Clínic
  4. 4Hospital del Mar
  5. 5Corporaciό Sanitària Taulí
  6. 6Hospital General de Hospitalet
  7. 7Hospital de Sant Joan Despí Moisès Broggi
  8. 8Hospital de Bellvitge, Barcelona, Spain


Background There are few data about Tocilizumab (TCZ) in monotherapy effectiveness in clinical practice conditions

Objectives To analyze the effectiveness TCZ monotherapy at medium/long term in clinical practice

Methods Observational, retrospective, multicenter, 2-year study of RA patients on TCZ monotherapy.We recorded: demographic and clinical data (duration of RA, RF and CCP antibodies, previous treatments and reason for its discontinuation); At baseline and at 3, 6, 9, 12, 18 and 24 months:RA activity (DAS-28 ESR index, TJC, SJC, ESR, CRP and % of patients in Remission or Low Disease Activity (LDA). Adverse effects were also recorded

Results 123 patients were included, with a mean age of 57.7±12.5 years and 85.4% females. Mean disease duration of 14.4±12.0 y; 67.5% and 59'3% were RF and anti-CCP positive. 98.4% had previously received conventional DMARD (2 DMARDs: 30.9% and ≥3 DMARDs: 38.2%), reasons for DMARD discontinuation were inefficacy (26%), adverse events (58.5), patient decision (8.9%) and other reasons (4.1%). 13% had not received prior biological DMARDs; 34.1% had received 1; 20.3% 2; 16.3% 3; 8.9% 4 and 6.5% ≥5)

Table 1

A relationship between Remission/LDA and disease duration and reason for discontinuation of prior conventional DMARD was not found. An association among the number of previous biological treatments and a low disease activity at 6 m (p<0.017), 9m (p<0.025) and 12m (p<0.028) was observed. 41 patients discontinued treatment (33.3%): 17due to inefficacy, 13 due to AE, 4 because of patient decision and 7 due to other reasons. No association between discontinuation of TCZ and duration of disease or number of previous biological DMARDs was found.

Conclusions In our experience, TCZ monotherapy is effective at medium/long term regardless of the duration of the disease and previous treatments, maintaining a high retention rate

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.